Lilly’s Tirzepatide Could Land Again on FDA Drug Shortage List, Opens Door for Compounders
The FDA on Friday announced that it would reconsider taking Eli Lilly’s type 2 diabetes and weight loss medication tirzepatide off its shortage list, a decision that could allow compounded versions of the drug back into the market, according to media …